Shares of Novogen Limited (NASDAQ:KZIA – Get Free Report) have been given an average rating of “Moderate Buy” by the five brokerages that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $23.75.
KZIA has been the subject of several research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Novogen in a research note on Tuesday, April 21st. Lake Street Capital initiated coverage on Novogen in a research note on Thursday, June 11th. They issued a “buy” rating and a $32.00 price objective for the company. Laidlaw initiated coverage on Novogen in a research note on Wednesday, April 15th. They issued a “buy” rating and a $25.00 price objective for the company. Finally, Wall Street Zen downgraded Novogen from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th.
Check Out Our Latest Stock Analysis on Novogen
Novogen Stock Up 3.5%
Novogen (NASDAQ:KZIA – Get Free Report) last released its quarterly earnings data on Saturday, February 14th. The company reported ($1.34) earnings per share for the quarter. The company had revenue of $4.89 million during the quarter. On average, analysts predict that Novogen will post -0.01 EPS for the current year.
About Novogen
Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.
Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.
Featured Stories
- Five stocks we like better than Novogen
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Receive News & Ratings for Novogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novogen and related companies with MarketBeat.com's FREE daily email newsletter.
